LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG, commonly referred to as LTS, is a leading global player in the pharmaceutical and medical device industry, headquartered in Andernach, Germany. Founded in 1981, the company has established itself as a pioneer in transdermal drug delivery systems, offering innovative solutions that enhance patient compliance and therapeutic efficacy. With a strong presence in Europe, North America, and Asia, LTS focuses on the development and manufacturing of advanced drug delivery technologies, including patches and films. Their unique approach combines cutting-edge research with state-of-the-art production capabilities, ensuring high-quality products tailored to meet diverse medical needs. Recognised for its commitment to excellence, LTS has achieved significant milestones, solidifying its market position as a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does LTS Lohmann Therapie-Systeme AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LTS Lohmann Therapie-Systeme AG's score of 35 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
LTS Lohmann Therapie-Systeme AG's reported carbon emissions
LTS Lohmann Therapie-Systeme AG, headquartered in Germany, has made significant commitments towards reducing its carbon emissions, although specific emissions data for the most recent year is currently unavailable. The company has set ambitious targets as part of its climate strategy, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050. In the near term, LTS Lohmann Therapie-Systeme AG has committed to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by 50% by 2030, using 2023 as the baseline year. Additionally, the company aims to achieve a 25% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, fuel- and energy-related activities, waste generated in operations, employee commuting, and end-of-life treatment of sold products, also by 2030. For the long term, LTS Lohmann Therapie-Systeme AG has set a target to reduce its absolute Scope 1 and Scope 2 emissions by 90% by 2050, alongside a similar 90% reduction in Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Overall, LTS Lohmann Therapie-Systeme AG is actively working towards substantial emissions reductions, demonstrating a strong commitment to sustainability and climate action in the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
LTS Lohmann Therapie-Systeme AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
